Global Journal of Medicine and Medical Sciences received 470 citations as per Google Scholar report
Mustafa Refae
Despite great efforts, end-stage heart failure (HF) remains a leading cause of morbidity and mortality. However, treatment of
advanced heart failure refractory to medical therapy is essentially limited to heart transplantation and LVAD. With significantly
limited donor heart availability, many patients die while waiting. Recent advances in technology and out-comes with VADS have
markedly changed the approach to advanced heart failure management. We reported 3 cases with non-ischemic cardiomyopathy
with chronic heart failure symptoms, recovered their LV systolic function after LVAD heart mate-II implantation and LV recovered to
have LVAD explanted. In conclusion, improvement in clinical and surgical expertise in LVAD has improved the quality of life in well
selected patient with advanced (HF) with bridge-to-recovery, LVAD has shown promising results of improved functional capacity,
quality of life and survival, however, successful LVAD in advanced (HF) is crucially dependent on proper patient selection.
Share this article